Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthiritis.
Over the past decade, we have delivered 14 new products to patients with serious diseases. Four of these products are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry.
To accelerate the discovery and development of important new therapies, we are complementing and enhancing our internal capabilities with our String of Pearls strategy of innovative alliances, partnerships and acquisitions.
As a BioPharma leader, we believe what sets us apart is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.
Contact
Woodmead North Office Park,
54 Maxwell Drive,
Woodmead, 2191,
Sandton,
Gauteng,
South Africa
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
